Bio-Techne (NASDAQ:TECH – Get Free Report) had its price target lowered by equities researchers at Wells Fargo & Company from $76.00 to $62.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 26.85% from the stock’s previous close.
Other analysts also recently issued research reports about the stock. TD Cowen reiterated a “buy” rating on shares of Bio-Techne in a report on Tuesday, March 17th. UBS Group reissued a “buy” rating and issued a $79.00 price target (up from $70.00) on shares of Bio-Techne in a research report on Thursday, February 5th. Evercore set a $50.00 price objective on shares of Bio-Techne in a research note on Thursday. Weiss Ratings lowered shares of Bio-Techne from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Finally, Benchmark reaffirmed a “buy” rating on shares of Bio-Techne in a research note on Tuesday, February 3rd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $67.54.
Read Our Latest Stock Report on TECH
Bio-Techne Price Performance
Bio-Techne (NASDAQ:TECH – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by ($0.02). Bio-Techne had a return on equity of 13.94% and a net margin of 6.67%.The firm had revenue of $311.42 million during the quarter, compared to analyst estimates of $316.11 million. During the same quarter in the previous year, the firm posted $0.56 earnings per share. The company’s quarterly revenue was down 1.5% on a year-over-year basis. Equities research analysts forecast that Bio-Techne will post 1.73 earnings per share for the current fiscal year.
Institutional Trading of Bio-Techne
A number of hedge funds have recently bought and sold shares of TECH. Danske Bank A S bought a new position in shares of Bio-Techne during the 4th quarter worth about $29,000. eCIO Inc. bought a new position in shares of Bio-Techne during the 4th quarter worth about $30,000. Measured Wealth Private Client Group LLC bought a new position in shares of Bio-Techne during the 3rd quarter worth about $32,000. iSAM Funds UK Ltd bought a new position in shares of Bio-Techne during the 3rd quarter worth about $33,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Bio-Techne by 506.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 562 shares during the period. 98.95% of the stock is owned by institutional investors.
Key Bio-Techne News
Here are the key news stories impacting Bio-Techne this week:
- Positive Sentiment: Management is targeting roughly 100 basis points of margin expansion in Q4 and expects organic growth to be approximately flat, which investors may view as credible margin-driven earnings leverage. Bio-Techne expects Q4 organic growth approximately flat while targeting ~100 bps margin expansion
- Positive Sentiment: Board declared a quarterly dividend of $0.08/share (payable May 29; record May 18), providing incremental income appeal and signalling cash-flow confidence. Bio-Techne Declares Dividend
- Positive Sentiment: Management highlighted strong growth in key product vectors (mid-single-digit Proteomic Analysis instruments, mid-teens Spatial Biology, ~50% GMP proteins ex fast?track customers), which could support future revenue recovery. Bio-Techne Releases Third Quarter Fiscal 2026 Results
- Neutral Sentiment: Full earnings call transcript and corporate release are available for investors to parse for details on shipment timing, GMP orders and end?market dynamics. Q3 2026 Earnings Call Transcript
- Negative Sentiment: Q3 revenue of $311.4M missed consensus (~$316M) and was down ~2% year-over-year; adjusted EPS $0.53 missed estimates and fell from $0.56 a year ago — the main driver of the initial selloff. TECH Stock Falls on Q3 Earnings & Revenue Miss, Operating Margin Up
- Negative Sentiment: Company cited weaker demand from U.S. academic customers due to funding cuts and timing of large commercial supply shipments (including prior-year GMP fast?track orders) as headwinds to growth. Bio-Techne misses revenue estimates as US academic funding cuts dent demand
- Negative Sentiment: Market reaction included a sharp intraday slide after the results; some outlets and scanners flagged the revenue/EPS miss as the key reason for selling pressure. Bio-Techne slides after fiscal Q3 results
Bio-Techne Company Profile
Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.
Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.
Further Reading
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
